 LEIDEN, Netherlands CAMBRIDGE, Mass., Nov. 16, 2020 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq: PRQR the Company, a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases IRDs, today reported its financial and operating results for the third quarter ended September 30, 2020 and provided a business update, including updated timeline guidance for the Companys clinical stage programs. 